Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

Synthesis of 1-(2-{2-[4-Fluoro-2-(4-[18F]fluorobenzoyl)phenyl]vinyloxy}ethyl)nipecotic Acid for PET imaging of GAT-1

Alexandra Sowa, Allen Brooks, Peter Scott and Michael Kilbourn
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1047;
Alexandra Sowa
1University of Michigan Ann Arbor MI United States
2University of Michigan Ann Arbor MI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allen Brooks
1University of Michigan Ann Arbor MI United States
2University of Michigan Ann Arbor MI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Scott
1University of Michigan Ann Arbor MI United States
2University of Michigan Ann Arbor MI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Kilbourn
1University of Michigan Ann Arbor MI United States
2University of Michigan Ann Arbor MI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1047

Objectives Availability of a positron emission tomography (PET) radioligand for the GABA transporter type 1 ( GAT-1) may facilitate the pre-synaptic imaging of GABA-ergic neurons. Changes in GABA-ergic neurotransmission are associated with a number of neurological (e.g. epilepsy) and psychiatric (e.g. schizophrenia, depression, Autism Spectrum Disorder, and anxiety) conditions. The objective of this work was to synthesize a GAT-1 selective PET radioligand based on a series of fluorinated unsymmetrical benzophenone-substituted nipecotic acid derivatives that have been recently described in the literature (Quandt G, et al. (2013) Bioorg Med Chem, 21, 3363).

Methods The initial target molecule chosen for radiolabeling was 1-(2-{2-[4-fluoro-2-(4-fluorobenzoyl)phenyl]-vinyloxy}ethyl)nipecotic acid, which had demonstrated in vitro inhibition of GABA uptake similar to tiagabine (FDA approved high-affinity GAT-1 inhibitor) (Quandt G, et al., 2013). As precursor the ethyl ester of the chloro-substituted analog (1-(2-{2-[4-fluoro-2-(4-chloro-benzoyl)phenyl]vinyloxy}ethyl)nipecotic acid) was prepared. That precursor was then treated with [18F]KF/K2.2.2 in DMF at 130 °C for 30 minutes, and the intermediate fluorine-18 labeled ester hydrolyzed to the acid with sodium hydroxide.

Results The [18F]fluorination was performed in a TRACERlab FXFN synthesis system. 1-(2-{2-[4-Fluoro-2-(4-[18F]fluorobenzoyl)phenyl]vinyloxy}ethyl)nipecotic acid was prepared in 13% radiochemical conversion from the chloro precursor.

Conclusions This work demonstrates the successful synthesis of a novel nipecotic acid derivative as a potential PET radioligand for the GABA transporter GAT-1. This radioligand and related nipecotic acid derivatives may facilitate in vitro and in vivo studies to better understand the changes to GABA-ergic neurotransmission in diseases and support the development of new treatments and therapeutics. Acknowledgements: Research was supported by NIH grant R21NS086758.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Synthesis of 1-(2-{2-[4-Fluoro-2-(4-[18F]fluorobenzoyl)phenyl]vinyloxy}ethyl)nipecotic Acid for PET imaging of GAT-1
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Synthesis of 1-(2-{2-[4-Fluoro-2-(4-[18F]fluorobenzoyl)phenyl]vinyloxy}ethyl)nipecotic Acid for PET imaging of GAT-1
Alexandra Sowa, Allen Brooks, Peter Scott, Michael Kilbourn
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1047;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthesis of 1-(2-{2-[4-Fluoro-2-(4-[18F]fluorobenzoyl)phenyl]vinyloxy}ethyl)nipecotic Acid for PET imaging of GAT-1
Alexandra Sowa, Allen Brooks, Peter Scott, Michael Kilbourn
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1047;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

SPECIAL MTA: Preclinical Probes for Neuroimaging Posters

  • [18F]FLT - A new stem cell label for in vivo tracking with positron emission tomography
  • Flourine-18 labeling of electron-rich 5-HT2A agonists
  • Synthesis and Evaluation of PET Radiotracers for the Presynaptic High-affinity Choline Transporter
Show more SPECIAL MTA: Preclinical Probes for Neuroimaging Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire